Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts also recently commented on INO. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price target (up from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday. Finally, HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.75.

Inovio Pharmaceuticals Stock Down 1.2%

NASDAQ:INO opened at $1.66 on Friday. Inovio Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $2.98. The firm has a market capitalization of $110.77 million, a PE ratio of -0.99 and a beta of 1.70. The firm has a 50-day moving average price of $1.65 and a 200 day moving average price of $2.05.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.68. The company had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.33 million. On average, research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. MCF Advisors LLC acquired a new position in Inovio Pharmaceuticals in the third quarter worth $26,000. SG Americas Securities LLC acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $27,000. Stephens Inc. AR bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at about $32,000. Focus Partners Wealth bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at about $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares in the last quarter. Institutional investors own 26.79% of the company’s stock.

Trending Headlines about Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.